Cubicin.com

We hope that you find this collection of medical websites useful. Select a specific discipline below to view the corresponding links.

Surgery | Nephrology | Internal Medicine | Infectious Disease

Surgery
American Association for the Surgery of Trauma
www.aast.org

American Surgical Association
www.americansurgical.info

MedQIC, Surgical Site Infections
www.medqic.org

Surgical Infection Society
www.sisna.org

Surgical Infection Society Europe
www.sis-e.org

Nephrology
American Society of Nephrology
www.asn-online.org

MayoClinic.com, Kidney Infection
www.mayoclinic.com/health/kidney-infection/DS00593

MedlinePlus, Kidney Infection
www.nlm.nih.gov/medlineplus/ency/article/000522.htm

Medscape, Nephrology
www.medscape.com/nephrology

National Kidney Foundation
www.kidney.org

Renal Physicians Association
www.renalmd.org

Internal Medicine
American Board of Internal Medicine
www.abim.org

Society of Hospital Medicine
www.hospitalmedicine.org

Journal of American Medical Association
www.jama.ama-assn.org

New England Journal of Medicine
www.content.nejm.org

Annals of Internal Medicine
www.annals.org

American College of Physicians
www.acponline.org

Society of General Internal Medicine
www.sgim.org

CDC
www.cdc.gov

Cleveland Clinic
www.clevelandclinic.org

Infectious Disease
Infectious Diseases Society of America (IDSA)
www.idsociety.org

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
www.icaac.org

ABX Guide
www.hopkins-abxguide.org

AMA Infectious Diseases
www.ama-assn.org/ama/pub/category/1797.html

American College of Physicians, ACP Online, Bioterrorism Resources
www.acponline.org/bioterro/index.html

Antibiotic Resistance Genes Online
www.argodb.org

Antibiotic Resistance Prevention and Control
www.hpa.org.uk/hpa/inter/arpac.htm

Centers for Disease Control, Antibiotic and Antimicrobial Resistance
www.cdc.gov/drugresistance

Centers for Disease Control, Infection Control in Healthcare Settings
www.cdc.gov/ncidod/dhqp/index.html

MayoClinic.com, Infectious Disease Center
www.mayoclinic.com/health/infectious-disease/ID99999

Medscape, Infectious Diseases
www.medscape.com/infectiousdiseases

Merck Manual, Infectious Diseases
www.merck.com/mmpe/sec14.html

National Center for Infectious Disease
www.cdc.gov/ncidod

Network on Antimicrobial Resistance and Staphyloccus aureus (NARSA)
www.narsa.net/content/default.jsp

Indications and Important Safety Information

CUBICIN® (daptomycin for injection) is indicated for the following infections:
- Complicated skin and skin structure infections caused by susceptible isolates of the following Gram-positive microorganisms: S. aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subspecies equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative or anaerobic organisms
- S. aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative or anaerobic organisms
The efficacy of CUBICIN in patients with left-sided infective endocarditis due to S. aureus has not been demonstrated. The clinical trial of CUBICIN in patients with S. aureus bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor. CUBICIN has not been studied in patients with prosthetic valve endocarditis or meningitis
Patients with persisting or relapsing S. aureus infection or poor clinical response should have repeat blood cultures. If a culture is positive for S. aureus, MIC susceptibility testing of the isolate should be performed using a standardized procedure, as well as diagnostic evaluation to rule out sequestered foci of infection. Appropriate surgical intervention (eg, debridement, removal of prosthetic devices, valve replacement surgery) and/or consideration of a change in antibiotic regimen may be required
CUBICIN is not indicated for the treatment of pneumonia
Clostridium difficile-associated diarrhea (CDAD) has been reported with the use of nearly antibacterial agents, including CUBICIN, and may range in severity from mild diarrhea to fatal colitis. CDAD has been reported to occur over 2 months post-antibiotic treatment. If CDAD is suspected, antibiotic treatment may need to be suspended
Patients receiving CUBICIN should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. In patients who receive CUBICIN, creatine phosphokinase (CPK) levels should be monitored weekly, and more frequently in patients who received recent prior or concomitant therapy with an HMG-CoA reductase inhibitor. In patients with renal insufficiency, both renal function and CPK should be monitored more frequently. Patients who demonstrate unexplained elevations in CPK while receiving CUBICIN should be monitored more frequently
CUBICIN should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK elevation >1000 U/L (~5 x ULN), or in patients without reported symptoms who have marked elevations in CPK >2000 U/L (≥10 x ULN)
Most adverse events reported in CUBICIN clinical trials were mild to moderate in intensity. The most common CUBICIN adverse events were anemia, constipation, diarrhea, nausea, vomiting, injection-site reactions, and headache

Please refer to full Prescribing Information

Home | Terms of Use | Privacy Policy | Site Map

Copyright ©2008 Cubist Pharmaceuticals, Inc., Lexington, MA, USA.
All rights reserved. CUBICIN is a registered trademark of Cubist Pharmaceuticals, Inc.
All other trademarks or registered trademarks are the property of their respective owners.